When will retatrutide be approved?
Reviewed 22 sourcesPublished by PepVault
Retatrutide isn't approved yet. Lilly plans to file with the FDA in early 2027. The review clock, the phase 3 dates and the court case, as of November 2026.

- Last reviewed
- Sources
- 22
- Questions
- 7
- Compounds
- 2
The short answer
As of November 2026, no regulator has approved retatrutide. Eli Lilly plans to file with the FDA in the first quarter of 2027. The FDA aims to decide on a new drug 10 months after a 60-day filing check, so about 12 months in all, or 8 months with priority review. By our arithmetic, that puts a decision between about September 2027 and March 2028.
- Not approved anywhere as of November 20, 2026; Drugs@FDA lists no approved product.
- Lilly's stated plan: file in the first quarter of 2027, once its manufacturing data package is done.
- FDA's goal clock: 60 days to file, then 10 months standard or 6 months priority, so a decision around September 2027 to March 2028.
- Lilly and the FDA are in court over whether retatrutide is a biologic or a drug; the review clock is the same either way.
Evidence: Dated facts as of November 20, 2026: Lilly's own statements, the FDA's published review goals and the court record. Trial results come from Lilly-funded phase 3 trials in adults; three are peer-reviewed, the rest are company toplines.

Is retatrutide approved yet?
No. As of November 20, 2026, Drugs@FDA, the FDA's database of approved drugs, lists no approved retatrutide product8. Lilly's own words, from its October 28, 2026 release: retatrutide 'has not been approved by FDA or any regulatory organization anywhere in the world', and 'anyone purporting to sell retatrutide to consumers is breaking the law'1.
What has happened comes before approval. Six phase 3 trials, the large final-stage studies a regulator judges a drug on, have reported results since December 20251, and three of them are now in peer-reviewed journals141516. Every one met its main goal. The next step is Lilly's application, and that has not been sent yet.

When will Lilly file for FDA approval?
In the first quarter of 2027, by Lilly's own plan. On July 23, 2026, alongside the TRIUMPH-2 and TRIUMPH-3 results, Lilly wrote that it 'is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package' and plans to submit 'in Q1 2027 for U.S. approval'2. The CMC package is the part of an application that shows the FDA how the drug is made, tested and kept stable, batch after batch, so by Lilly's account the manufacturing file, not the trials, is what remains.
Lilly repeated the plan on September 29, 20263, and told the federal appeals court on October 8, 2026 that it 'plans to file its application for retatrutide's approval no later than the first quarter of 2027'4. Lilly's third-quarter report of October 29, 2026 lists the positive phase 3 trials and no filing21, so as of November 20, 2026 the application is still to come.
How long does the FDA take to review a new drug?
The FDA's clock has two parts. First, it has 60 days to decide whether the application is complete enough to review, called the filing date. Then, for a new molecule, its goal is to 'review and act on 90 percent of standard' applications 'within 10 months of the 60-day filing date', or within 6 months for a priority review5. That is about 12 months from the day the application arrives, or about 8.
Priority review goes to a drug that 'would be significant improvements in the safety or effectiveness of the treatment' of a serious condition6. Lilly has not said whether it will ask for it. A large new data set sent during the review can 'extend the goal date by three months'5.
| Review path | Goal after the 60-day filing date | Decision if submitted Jan 1, 2027 | Decision if submitted Mar 31, 2027 |
|---|---|---|---|
| Priority review | 6 months5 | about Sep 2, 2027 | about Nov 30, 2027 |
| Standard review | 10 months5 | about Jan 2, 2028 | about Mar 30, 2028 |
| Standard, with a major amendment | 13 months5 | about Apr 2, 2028 | about Jun 30, 2028 |
| National priority voucher | 1-2 month target7 | none named for retatrutide7 | none named for retatrutide7 |
The dates are our arithmetic on the FDA's published goals, not a forecast from Lilly or the FDA. The FDA aims to meet each goal for 90% of applications, and an approval is never assured: the decision can also be a request for more data.
The fastest route is the FDA's national priority voucher, a pilot that targets a decision 1 to 2 months after a complete application7. Lilly's GLP-1 pill orforglipron was awarded one in November 202522. None of the FDA's voucher announcements through October 2026 names retatrutide7, and Lilly has not said it holds one, so the table plans on the normal clock.
Why are Lilly and the FDA in court over retatrutide?
Because they disagree on what kind of product it is. Lilly asked the FDA in November 2023 to classify retatrutide as a biological product, the class that includes proteins, which is approved through a biologics license application (BLA)9. On March 18, 2024, the FDA classified it as a drug instead, which goes through a new drug application (NDA)9. The line is size: under FDA's rule a protein has more than 40 alpha amino acids, the standard building blocks of proteins. Lilly counts 41 units in retatrutide; the FDA counts at most 40 alpha amino acids plus one that is not9.
- September 30, 2025: a federal court in Indiana upheld the FDA's finding that retatrutide is not a protein, set aside its finding that retatrutide is not 'analogous' to one, and sent that question back to the agency9.
- February 12, 2026: Lilly appealed to the Seventh Circuit, case No. 26-130110.
- September 24, 2026: the appeals court heard oral argument and asked both sides whether it can hear the appeal at all, with answers due October 811.
- October 2, 2026: the FDA decided again that retatrutide is not analogous to a protein12.
- As of November 20, 2026: no ruling from the appeals court in the record we could read412.
For the approval date, the fight matters less than it sounds. The FDA's own court brief says that 'regardless of which statute governs, Lilly's product will be subject to a detailed FDA review process'10, and the goals letter sets the same 10- and 6-month clocks for a new-molecule NDA and an original BLA5. What the label changes is the business around the drug: biologics get 'a substantially longer exclusivity period before follow-on products can enter the market'10. Lilly told the court it needs to know which pathway to file under4. Lilly's public plan names a BLA3; if the FDA's classification stands, retatrutide is regulated as a drug, under the law that governs new drug applications1012.
Which retatrutide trials are done, and which are still running?
ClinicalTrials.gov lists 14 phase 3 trials of retatrutide, all sponsored by Eli Lilly17. Six have reported topline results, the first summary of a trial's main result; the others run into 2027 and beyond. Weight results are each trial's highest dose, as the source reported it. The dates are the registry's primary completion dates, when the main measurement ends, read on November 20, 2026.
| Trial | Who | Status, Nov 20, 2026 | Primary completion | Result so far |
|---|---|---|---|---|
| TRIUMPH-4, NCT05931367 | Obesity and knee arthritis | Completed | Nov 14, 2025 | 28.7% weight loss at 68 weeks (Lilly, Dec 11, 2025)13 |
| TRANSCEND-T2D-1, NCT06354660 | Type 2 diabetes, no other drug | Completed | Jan 22, 2026 | HbA1c down 1.94 points vs 0.81 on placebo at 40 weeks16 |
| TRIUMPH-1, NCT05929066 | Obesity, no diabetes | Completed | Apr 6, 2026 | 25.0% weight loss at 80 weeks vs 3.9%14 |
| TRIUMPH-3, NCT05882045 | Severe obesity and heart disease | Completed | Apr 16, 2026 | 22.6% weight loss at 80 weeks (Lilly, Jul 23, 2026)2 |
| TRIUMPH-2, NCT05929079 | Obesity and type 2 diabetes | Completed | Jun 16, 2026 | 18.8% weight loss at 80 weeks vs 5.1%15 |
| TRANSCEND-T2D-2, NCT06260722 | Type 2 diabetes, against Ozempic 2 mg | Active, not recruiting | Aug 27, 2026 | 20.9% weight loss vs 9.4% at 80 weeks (Lilly, Oct 28, 2026)1 |
| TRANSCEND-T2D-3, NCT06297603 | Type 2 diabetes with kidney impairment | Active, not recruiting | Oct 26, 2026 | None published |
| TRIUMPH-5, NCT06662383 | Obesity, against tirzepatide | Active, not recruiting | Nov 2026 (estimated) | None yet20 |
| TRIUMPH-8, NCT07232719 | Obesity, no diabetes (phase 3b) | Active, not recruiting | Jun 2027 (estimated) | None yet |
| TRIUMPH-7, NCT07035093 | Obesity and low back pain | Active, not recruiting | Sep 2027 (estimated) | None yet |
| TRIUMPH-6, NCT06859268 | Keeping weight off (phase 3b) | Active, not recruiting | Apr 2028 (estimated) | None yet |
| TRIUMPH-9, NCT07357415 | Dose step schemes (phase 3b) | Active, not recruiting | Oct 2028 (estimated) | None yet |
| TRIUMPH-Outcomes, NCT06383390 | Heart and kidney outcomes, 10,000 people | Active, not recruiting | Feb 2029 (estimated) | None yet |
| SYNERGY-Outcomes, NCT07165028 | Fatty liver disease, several drugs | Recruiting | Aug 2030 (estimated) | None yet |
Lilly's releases quote the efficacy estimand, the result had everyone stayed on the drug; the journals quote the treatment-regimen estimand, which counts everyone randomised whether or not they kept taking it, so their numbers run lower. All 14 trials are in adults.
An approval covers only the uses on its label, and the first application need not include every trial above. Lilly has not said which uses its first filing will ask for. The weight and diabetes trials were the ones complete by mid-2026, and the doses they tested are in our guide to retatrutide's trial step-ups. Our study pages at pepvault.app/research/retatrutide-triumph-1-2026 and pepvault.app/research/retatrutide-transcend-t2d-1-2026 tell those two trials in plain words.
Is retatrutide available anywhere before approval?
Only inside Lilly's program. Its trials are the legal route, and as of November 20, 2026 the one phase 3 trial still recruiting is the fatty liver study17. Since June 5, 2026 the registry also lists a pre-approval expanded access program: a treating physician can request it for an adult with a BMI of 35 or more despite the highest available dose of a weight drug, two or more serious obesity-related conditions and no reachable trial19.
A pharmacy cannot make it either: the FDA writes that 'retatrutide and cagrilintide cannot be used in compounding under federal law'18. The legal status page at pepvault.app/peptides/retatrutide/legal-status sets the FDA, DEA and WADA positions side by side, and our guide Is retatrutide safe? covers the FDA's warnings over products sold outside the trials.
What should you watch for next?
- TRIUMPH-5, retatrutide against tirzepatide, reaches its primary completion in November 2026 (estimated)20. Lilly's toplines have come one to two months after that date so far (TRIUMPH-413, TRANSCEND-T2D-21).
- The filing itself, planned for the first quarter of 20273. The FDA's acceptance comes about 60 days later, and the goal date runs from there5.
- The Seventh Circuit, on whether Lilly can appeal now and, if so, whether retatrutide is a protein1112.
- The label, if the FDA approves: the first approved dose, step schedule and uses. Until then every retatrutide dose is a trial's.
Retatrutide works on three hormone receptors, GIP, GLP-1 and glucagon, where tirzepatide works on two; pepvault.app/peptides/compare/retatrutide-vs-tirzepatide sets the two side by side. Tirzepatide is already approved, and for most people the drug that is legal today is the one to talk to a prescriber about.
If you're on an approved weekly GLP-1 now, PepVault logs each shot, reminds you on the day and charts your weigh-ins, so your record is ready for whoever prescribes the next step. Track your weight in PepVault
Sources
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2), with FAQ. Press release, Oct 28, 2026. prnewswire.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. prnewswire.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. prnewswire.com
- Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Supplemental brief of appellant, Oct 8, 2026 (Document 47). storage.courtlistener.com
- US Food and Drug Administration. PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (the PDUFA VII goals letter). fda.gov
- US Food and Drug Administration. Priority Review (content current as of Jan 4, 2018). fda.gov
- US Food and Drug Administration. Commissioner's National Priority Voucher (CNPV) Pilot Program (content current as of Oct 19, 2026). fda.gov
- US Food and Drug Administration. Drugs@FDA data (openFDA), search for retatrutide: no matches, read Nov 20, 2026. api.fda.gov
- Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503-TWP-KMB (S.D. Ind.). Order on cross-motions for summary judgment, Sept 30, 2025. govinfo.gov
- Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Brief for appellees (FDA and HHS), May 15, 2026 (Document 23). storage.courtlistener.com
- Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Order directing supplemental memoranda on appellate jurisdiction, Sept 24, 2026 (Document 45). storage.courtlistener.com
- Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Supplemental letter brief for the government, Oct 8, 2026 (Document 46). storage.courtlistener.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release, Dec 11, 2025. prnewswire.com
- Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
- Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
- Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. PubMed 42250575
- ClinicalTrials.gov. Phase 3 studies of retatrutide (LY3437943), all sponsored by Eli Lilly and Company; API v2 records read Nov 20, 2026. clinicaltrials.gov
- US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026). fda.gov
- ClinicalTrials.gov NCT07629401. Pre-approval expanded access of retatrutide (LY3437943) (sponsor Eli Lilly and Company; first posted June 5, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT06662383 (TRIUMPH-5). A study of retatrutide (LY3437943) compared to tirzepatide (LY3298176) in adults who have obesity (phase 3; sponsor Eli Lilly and Company). clinicaltrials.gov
- Eli Lilly and Company. Form 10-Q for the quarter ended Sept 30, 2026, filed Oct 29, 2026 (Compound Development). sec.gov
- US Food and Drug Administration. FDA awards second batch of national priority vouchers. Press release, Nov 6, 2025. fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.